Our experiments using Cdc42-, Rac1-, and Rho-blocking agents revealed that the Cdc42 GTPase inhibitor resulted in a dose-dependent decrease in cell attachment of all four gastric cancer cell lines. The gene discussed is RAC1; the disease is gastric cancer.